Adverum Biotechnologies (ADVM) Competitors $7.90 -0.04 (-0.50%) (As of 11/7/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ADVM vs. BDTX, CHRS, CRTX, CCCC, SGMO, TECX, MREO, NGNE, ANAB, and EXAIShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Black Diamond Therapeutics (BDTX), Coherus BioSciences (CHRS), Cortexyme (CRTX), C4 Therapeutics (CCCC), Sangamo Therapeutics (SGMO), Tectonic Therapeutic (TECX), Mereo BioPharma Group (MREO), Neurogene (NGNE), AnaptysBio (ANAB), and Exscientia (EXAI). These companies are all part of the "medical" sector. Adverum Biotechnologies vs. Black Diamond Therapeutics Coherus BioSciences Cortexyme C4 Therapeutics Sangamo Therapeutics Tectonic Therapeutic Mereo BioPharma Group Neurogene AnaptysBio Exscientia Black Diamond Therapeutics (NASDAQ:BDTX) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability. Does the MarketBeat Community favor BDTX or ADVM? Adverum Biotechnologies received 317 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 60.43% of users gave Adverum Biotechnologies an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% Adverum BiotechnologiesOutperform Votes36860.43% Underperform Votes24139.57% Does the media refer more to BDTX or ADVM? In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 10 articles in the media. Black Diamond Therapeutics' average media sentiment score of 0.87 beat Adverum Biotechnologies' score of -0.33 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adverum Biotechnologies 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate BDTX or ADVM? Black Diamond Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 385.89%. Adverum Biotechnologies has a consensus target price of $27.83, indicating a potential upside of 249.23%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than Adverum Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more risk & volatility, BDTX or ADVM? Black Diamond Therapeutics has a beta of 2.51, indicating that its stock price is 151% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Do institutionals & insiders have more ownership in BDTX or ADVM? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is BDTX or ADVM more profitable? Black Diamond Therapeutics' return on equity of -69.08% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -69.08% -51.68% Adverum Biotechnologies N/A -74.45%-44.81% Which has higher earnings and valuation, BDTX or ADVM? Black Diamond Therapeutics has higher earnings, but lower revenue than Adverum Biotechnologies. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$82.44M-$1.33-2.40Adverum Biotechnologies$3.60M46.05-$117.17M-$7.99-1.00 SummaryBlack Diamond Therapeutics beats Adverum Biotechnologies on 10 of the 15 factors compared between the two stocks. Ad DTIDid you miss 1000% bitcoin gains?Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this... Because a new blockchain is taking the world by storm… It’s seeing rapid adoption amongst crypto fans… And just now starting to break into the mainstream. While I cannot promise future returns or against losses… This might not just be another chance at Bitcoin-like gains… It could be EVEN bigger. But this market is moving fast… So if you want a shot at getting in on what could be the ground floorClick Here for Details. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.78M$3.22B$5.29B$8.95BDividend YieldN/A1.75%5.10%4.03%P/E Ratio-1.0013.26118.6516.48Price / Sales46.05356.231,383.74107.52Price / CashN/A147.1838.9033.99Price / Book0.965.304.925.37Net Income-$117.17M-$42.25M$118.17M$223.73M7 Day Performance9.18%15.05%4.59%4.74%1 Month Performance7.12%19.73%10.38%7.55%1 Year Performance-12.42%46.88%37.71%28.40% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies3.6783 of 5 stars$7.90-0.5%$27.83+252.3%-16.9%$164.33M$3.60M-0.99190Earnings ReportAnalyst ForecastAnalyst RevisionBDTXBlack Diamond Therapeutics2.524 of 5 stars$2.89+5.5%N/A+72.3%$163.30MN/A-1.9390Earnings ReportAnalyst ForecastCHRSCoherus BioSciences3.7545 of 5 stars$0.72-2.7%N/A-79.6%$83.30M$257.24M-1.81246Analyst ForecastNews CoverageGap UpCRTXCortexymeN/A$1.54-4.9%N/A+48.3%$46.43MN/A-0.5255Gap UpCCCCC4 Therapeutics2.0215 of 5 stars$5.61+5.3%N/A+229.8%$389.00M$20.76M-2.95150Earnings ReportNews CoverageGap UpSGMOSangamo Therapeutics2.247 of 5 stars$1.88+10.6%N/A+459.3%$391.46M$12.28M-1.36480Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageTECXTectonic Therapeutic2.7774 of 5 stars$40.88-0.4%N/AN/A$602.16MN/A-7.91120Upcoming EarningsHigh Trading VolumeMREOMereo BioPharma Group2.4117 of 5 stars$4.28+1.7%N/A+98.1%$600.30M$1M0.0040NGNENeurogene0.8978 of 5 stars$46.07+4.7%N/AN/A$598.45MN/A0.0090Upcoming EarningsAnalyst RevisionANABAnaptysBio2.9226 of 5 stars$21.68+0.2%N/A+33.2%$594.77M$30.47M-3.41100Earnings ReportAnalyst ForecastEXAIExscientia1.3489 of 5 stars$4.90+0.8%N/A-4.3%$592.36M$25.60M-3.77280Upcoming EarningsNews Coverage Related Companies and Tools Related Companies BDTX Alternatives CHRS Alternatives CRTX Alternatives CCCC Alternatives SGMO Alternatives TECX Alternatives MREO Alternatives NGNE Alternatives ANAB Alternatives EXAI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADVM) was last updated on 11/7/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredStrange new catalyst for gold ($5,000 possible?)Gold: Now legal tender Most Americans missed this big story, but 1 in 5 states have now made gold and silve...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADVM Stock Alerts